Autism Pipeline Review and Market Analysis, H2 2015

Autism - Pipeline Review, H2 2015 provides an overview of the Autism's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Autism, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Autism and special features on late-stage and discontinued projects.

Companies mentioned in this report are Addex Therapeutics Ltd, BioCrea GmbH, BrainStorm Cell Therapeutics Inc., Cellceutix Corporation, Confluence Pharmaceuticals LLC, Curemark, LLC, Egenix, Inc., F. Hoffmann-La Roche Ltd., Heptares Therapeutics Limited, Intra-Cellular Therapies, Inc., MedDay, Merz Pharma GmbH & Co. KgaA, Mnemosyne Pharmaceuticals, Inc., Omeros Corporation, Otsuka Holdings Co., Ltd., Retrophin Inc., Reviva Pharmaceuticals Inc., Saniona AB, Sumitomo Dainippon Pharma Co., Ltd.

Purchase a copy of this report at http://www.rnrmarketresearch.com/contacts/purchase?rname=415862 . (This is a premium report price at US$2000 for a single user PDF license)

The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information.

Scope:

• The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

• The report reviews key players involved in...